Toggle light / dark theme

A new study finds a chemical formed when we digest a widely used sweetener is “genotoxic,” meaning it breaks up DNA. The chemical is also found in trace amounts in the sweetener itself, and the finding raises questions about how the sweetener may contribute to health problems.

At issue is sucralose, a widely used artificial sweetener sold under the trade name Splenda®. Previous work by the same research team established that several fat-soluble compounds are produced in the gut after sucralose ingestion. One of these compounds is sucralose-6-acetate.

Our new work establishes that sucralose-6-acetate is genotoxic. We also found that trace amounts of sucralose-6-acetate can be found in off-the-shelf sucralose, even before it is consumed and metabolized.

Thinking of X-rays might trigger memories of broken bones or dental check-ups. But this extremely energetic light can show us more than just our bones: it is also used to study the molecular world, even biochemical reactions in real-time. One issue, though, is that researchers have never been able to study a single atom with X-rays. Until now.

Scientists have been able to characterize a single atom using X-rays. Not only they were able to distinguish the type of atoms they were seeing (there were two different ones), but they also managed to study the chemical behavior these atoms were showing.

“Atoms can be routinely imaged with scanning probe microscopes, but without X-rays, one cannot tell what they are made of. We can now detect exactly the type of a particular atom, one atom-at-a-time, and can simultaneously measure its chemical state,” senior author Professor Saw Wai Hla, from the University of Ohio and the Argonne National Laboratory, said in a statement.

Jo Cameron is a 75-year-old Scottish woman who has gone through life without experiencing significant pain of any kind. Even major surgery and childbirth failed to deliver the discomfort most of us would experience.

According to an interview with the BBC in 2019, Cameron only knows her skin is burning if she smells or sees it. To her, suffering is nothing more than an abstract concept.

The quirk that Cameron was born with is shared with just a few other people in th e world. Called congenital analgesia, it is a one-in-a-million condition with multiple genetic causes that may come with other symptoms, such as sweating more or having no sense of smell.

Geneticists have unearthed a major event in the ancient history of sturgeons and paddlefish that has significant implications for the way we understand evolution. They have pinpointed a previously hidden “whole genome duplication” (WGD) in the common ancestor of these species, which seemingly opened the door to genetic variations that may have conferred an advantage around the time of a major mass extinction some 200 million years ago.

The big-picture finding suggests that there may be many more overlooked, shared WGDs in other species before periods of extreme environmental upheaval throughout Earth’s tumultuous history.

The research, led by Professor Aoife McLysaght and Dr. Anthony Redmond from Trinity College Dublin’s School of Genetics and Microbiology, has just been published in Nature Communications.

A drug that was originally developed to treat diabetes and severe overweight might also help people with nicotine dependence, concludes new research from the University of Copenhagen.

Smoking is one of the to public health. According to new data from the Danish Health Authority, 15,920 Danes die every year because of their addiction to cigarettes.

And 75% of smokers want to quit.

Researchers discover Chimno, the gene responsible for the juvenile stage in insects. This gene is present in mammals and could play a key role in cancerous processes.

The study, which was published in the journal eLife and led by the Institute for Evolutionary Biology (IBE, CSIC-UPF) and the IRB Barcelona, has revealed that the Chinmo gene is responsible for establishing the juvenile stage in insects. It also confirms that the Br-C and E93 genes play a regulatory role in insect maturity. These genes, which are also present in humans, act as a promoter and as a suppressor, respectively, of cancerous processes.

The results of the research, which was carried out with the fruit fly Drosophila melanogaster and the cockroach Blatella germanica, reveal that these genes have been conserved throughout the evolution of insects. Therefore, it is believed that they could play a key role in the evolution of metamorphosis.

A long, long time ago, back in the early exciting days of raltegravir, the first HIV integrase inhibitor, we learned something important from a clinical trial with disappointing results. The trial bore the (barely) hidden name of the company that developed the drug — SWITCHMRK, get it? — and had a profound impact on how we managed virologically suppressed patients for years.

What did we learn? Namely, that it was risky to switch stable people from their “high resistance barrier” regimen of lopinavir/ritonavir plus NRTIs to raltegravir plus NRTIs if they harbored viruses with NRTI resistance. Some of the participants who had a history of treatment failure who switched ended up experiencing virologic rebound with integrase inhibitor resistance, which made the switch to raltegravir not noninferior (sorry for the double negative) to continuing lopinavir/ritonavir.

The interpretation was that despite the potency and excellent tolerability of raltegravir — massively better than lopinavir/ritonavir — it wasn’t enough to maintain viral suppression reliably unless the NRTIs were also fully active. Based on these results, for years we steered clear of use of this valuable drug class in any setting where we couldn’t use at least one other fully active drug.